JAK/STAT Signaling

Products for JAK/STAT Signaling
- Cat.No. Product Name Information
-
GN10742
Homoharringtonine
-
GN10741
Garcinone D
-
GN10705
Alantolactone
-
GN10696
Garcinone C
-
GN10627
Atractylenolide I
-
GN10624
Scutellarin
-
GN10501
Cryptotanshinone
-
GN10442
Curculigoside
-
GN10436
Morusin
-
GN10314
Picroside I
-
GN10282
Vitexicarpin (Casticin)
-
GN10164
Saikosaponin D
-
GN10115
Diosgenin
-
GC15980
WP1066
An inhibitor of STAT3
-
GC25992
TG-89
TG-89 is an inhibitor of JAK2 with IC50 of 11.2 μM.
-
GC25899
SC-1
SC-1 (1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea, STAT3-IN-7), a Sorafenib analogue and potently inhibits the phosphorylation of STAT3, induces cell apoptosis through SHP-1 dependent STAT3 inactivation.
-
GC25869
RO495
RO495 (CS-2667) is a potent inhibitor of Non-receptor tyrosine-protein kinase 2 (TYK2).
-
GC25559
Lapatinib (GW-572016) Ditosylate
Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
-
GC25219
CH7233163
CH7233163 is a non-covalent ATP competitive inhibitor of EGFR-tyrosine kinase with antitumor activities against tumor with EGFR-Del19/T790M/C797S.
-
GC25168
Brepocitinib (PF-06700841)
Brepocitinib (PF-06700841, PF-841) is a potent inhibitor of Tyk2 and Jak1 with IC50s of 23 nM, 17 nM, 77 nM for Tyk2, Jak1 and Jak2 respectively. It has appropriate in-family selectivity against JAK2 and JAK3.
-
GC68440
EGFR-IN-69
-
GC68430
Selatinib
-
GC68378
GDC-4379
-
GC68321
O-Desmethyl gefitinib-d8
-
GC68304
Margetuximab
-
GC68000
JAK-IN-23
-
GC67958
HP590
-
GC67867
VVD-118313
-
GC67860
JBJ-09-063 TFA
-
GC67779
STX-0119
-
GC67759
Lapatinib-d4
-
GC67749
Amivantamab
-
GC67706
LY5
-
GC67690
JBJ-09-063 hydrochloride
-
GC52293
STAT3 Inhibitor 4m
A STAT3 inhibitor
-
GC66432
EAI001
EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC50 value of 24 nM for EGFRL858R/T790M. EAI001 can be used for research of cancer.
-
GC66428
EGFR-IN-5
EGFR-IN-5 is a EGFR inhibitor with IC50s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFRL858R, EGFRL858R/T790M, and EGFRL858R/T790M/C797S, respectively.
-
GC66405
Panitumumab
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer.
-
GC66333
Panitumumab (anti-EGFR)
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer.
-
GC66329
NDI-034858
NDI-034858 is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM.
-
GC65992
FGFR2-IN-3
FGFR2-IN-3 is an orally active selective inhibitor of FGFR2.
-
GC65991
FGFR2-IN-3 hydrochloride
FGFR2-IN-3 hydrochloride is an orally active selective inhibitor of FGFR2.
-
GC65974
EGFR-IN-9
EGFR-IN-9 (Compound 8) is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity.
-
GC65572
EGFR Protein Tyrosine Kinase Substrate
EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate.
-
GC65453
JAK-IN-3
JAK-IN-3 (compound 22) is a potent JAK inhibitor, with IC50 values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively.
-
GC65436
JND3229
JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma.
-
GC65405
JAK2-IN-6
JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective JAK2 inhibitor with an IC50 of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells.
-
GC65387
Tyk2-IN-5
Tyk2-IN-5 (compound 6) is a highly potent, selective and orally active Tyk2 inhibitor and targets the JH2 domain, with a Ki of 0.086 nM for Tyk2 JH2 and an IC50 of 25 nM for IFNα.
-
GC65344
STAT5-IN-2
STAT5-IN-2 is a STAT5 inhibitor, extracted from reference 1, example 17f. STAT5-IN-2 has potent antileukemic effect.
-
GC65310
TAS0728
TAS0728 is a potent, selective, orally active, irreversible and covalent-binding HER2 inhibitor, with an IC50 of 13 nM. TAS0728 also shows IC50s of 4.9, 8.5, 31, 65, 33, 25 and 86 nM for BMX、HER4、BLK、EGFR、JAK3、SLK and LOK respectively. Furthermore, TAS0728 exhibits robust and sustained inhibition of the phosphorylation of HER2
-
GC65278
PIM1-IN-1
PIM1-IN-1 is a potent and highly selective PIM1/3 inhibitor, with IC50s of 7, 5530 and 70 nM for PIM1, PIM2, and PIM3, respectively, inhibits the phosphorylation of BAD, a downstream target of PIM, with an EC50 of 262 nM. PIM1-IN-1 shows no obvious effect on FLT3 or hERG binding. Antiproliferative and anti-cancer activity.
-
GC65201
Quercetagetin
Quercetagetin (6-Hydroxyquercetin) is a flavonoid.
-
GC65020
Danvatirsen
Danvatirsen is an antisense oligonucleotide targeting STAT3 with potential antitumor activity. Danvatirsen binds to STAT3 mRNA, thereby inhibiting translation of the transcript. Suppression of STAT3 expression induces tumor cell apoptosis and decreases tumor cell growth.
-
GC64959
JAK/HDAC-IN-1
JAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows IC50s of 4 and 2 nM for JAK2 and HDAC, respectively.
-
GC64891
YM-341619
YM-341619 (AS1617612) is a potent and orally active STAT6 inhibitor with an IC50 of 0.70 nM.
-
GC64774
SEL24-B489
SEL24-B489 is a potent, type I, orally active, dual PIM and FLT3-ITD inhibitor, with Kd values of 2 nM for PIM1, 2 nM for PIM2 and 3 nM for PIM3, respectively.
-
GC64770
Oritinib
Oritinib (SH-1028), an irreversible third-generation EGFR TKI, overcomes T790M-mediated resistance in non-small cell lung cancer. Oritinib (SH-1028), a mutant-selective inhibitor of EGFR kinase activity, inhibits EGFRWT, EGFRL858R, EGFRL861Q, EGFRL858R/T790M, EGFRd746-750 and EGFRd746-750/T790M kinases, with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM, respectively.
-
GC64710
MC-Val-Cit-PAB-Amide-TLR7 agonist 4
MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate.
-
GC64701
Povorcitinib
Povorcitinib is a potent and selective inhibitor of JAK1.
-
GC64700
Povorcitinib phosphate
-
GC64497
EGFR-IN-17
EGFR-IN-17 is a potent and selective inhibitor of the epidermal growth factor receptor ( IC50 0.0002 μM) to overcome C797S-mediated resistance.
-
GC64398
Almonertinib mesylate
Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer.
-
GC64372
Lorpucitinib
Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease.
-
GC64302
BAY 2476568
BAY 2476568 is a potent and selective EGFR inhibitor, with IC50s of < 0.2 nM for wild-type EGFR and several mutations (EGFRR ex20insSVD, EGFRR ex20insASV, EGFRR ex20insNPG).
-
GC64108
Ifidancitinib
Ifidancitinib (ATI-50002) is a potent and selective inhibitor of JAK kinases 1/3.
-
GC64039
Disitamab vedotin
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.
-
GC64017
Befotertinib
Befotertinib (D-0316) is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC).
-
GC63910
BLU-945
BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC).
-
GC63864
(E/Z)-Zotiraciclib hydrochloride
(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent CDK2, JAK2, and FLT3 inhibitor.
-
GC63797
(S)-Sunvozertinib
(S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against EGFR exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC50=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively). (S)-Sunvozertinib also inhibits BTK.
-
GC63204
Stafib-2
Stafib-2 is a potent and selctive inhibitor of the transcription factor STAT5b, with an IC50 of 82 nM and 1.7 μM for STAT5b and STAT5a, respectively.
-
GC63203
Stafia-1-dipivaloyloxymethyl ester
Stafia-1-dipivaloyloxymethyl ester (compound 27, 0-200 μM) decreases pSTAT5a expression significantly, and has no obvious inhibition on pSTAT5b.
-
GC49139
CAY10784
A STAT3 inhibitor
-
GC62559
Stafia-1
Stafia-1 is a potent STAT5a inhibitor (K i=10.9 μM, IC50=22.2 μM). Stafia-1 displays high selectivity over STAT5b and other STAT family members.
-
GC62272
AC-4-130
AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML).
-
GC62254
Stafib-1
Stafib-1 is the first selective inhibitor of the STAT5b SH2 domain, with a Ki of 44 nM and an IC50 of 154 nM.
-
GC61807
(E/Z)-AG490
(E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.
-
GC61627
Ochromycinone
Ochromycinone ((Rac)-STA-21) is a natural antibiotic and a STAT3 inhibitor.
-
GC61574
AS1810722
AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.9 nM.
-
GC61524
SC-43
SC-43, a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis. SC-43 has anti-fibrotic and anticancer effects.
-
GC48839
Nifuroxazide-d4
An internal standard for the quantification of nifuroxazide
-
GC47061
CAY10763
A dual inhibitor of IDO1 and STAT3 activation
-
GC46503
2-(1,8-Naphthyridin-2-yl)phenol
2-(1,8-Naphthyridin-2-yl)phenol is a selective enhancer of STAT1 transcription. 2-(1,8-Naphthyridin-2-yl)phenol can enhance the ability of IFN-γ to inhibit the proliferation of human breast cancer and fibrosarcoma cells.
-
GC60586
Angoline hydrochloride
Angoline hydrochloride is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline hydrochloride inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation.
-
GC60585
Angoline
Angoline is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation.
-
GC50343
HJC 0416 hydrochloride
STAT3 inhibitor
-
GC39081
Reticuline
Reticuline shows anti-inflammatory effects through JAK2/STAT3 and NF-κB signaling pathways.
-
GC39022
Tetramethylcurcumin
Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain.
-
GC38737
AS2863619 free base
AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells for the treatment of various immunological diseases.
-
GC38736
AS2863619
A dual inhibitor of Cdk8 and Cdk19
-
GC45756
Pimozide-d4
An internal standard for the quantification of pimozide
-
GC38402
BI-4020
A fourth-generation and non-covalent EGFR tyrosine kinase inhibitor
-
GC38386
Golotimod hydrochloride
Golotimod hydrochloride (SCV 07 hydrochloride), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function.
-
GC38350
Epertinib hydrochloride
Epertinib hydrochloride (S-22611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib hydrochloride shows potent antitumor activity.
-
GC38180
Cyasterone
-
GC38125
Tyrphostin AG30
Tyrphostin AG30 (AG30) is a potent and selective EGFR tyrosine kinase inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts.
-
GC38081
Theliatinib
Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective EGFR inhibitor with a Ki of 0.05 nM and an IC50 of 3 nM. Theliatinib has an IC50 of 22 nM for EGFR T790M/L858R mutant. Theliatinib shows >50-fold selectivity for EGFR than other kinases. Anti-tumor activity.
-
GC38044
Fraxinellone
-
GC38006
β-Hydroxyisovalerylshikonin
Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermium radix, acts as a potent inhibitor of protein tyrosine kinases (PTK), with IC50s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively. Beta-hydroxyisovalerylshikonin is effective against a wide variety of tumor cell lines, and most efficiently induces cell-death in NCI-H522 and DMS114 cells.
-
GC37971
ZM39923
ZM39923 is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM.